Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma

BACKGROUND: Thymic stromal lymphopoietin (TSLP) is a key upstream regulator driving allergic inflammatory responses. We evaluated the efficacy and safety of ecleralimab, a potent inhaled neutralising antibody fragment against human TSLP, using allergen inhalation challenge (AIC) in subjects with mil...

Descripción completa

Detalles Bibliográficos
Autores principales: Gauvreau, Gail M., Hohlfeld, Jens M., FitzGerald, J. Mark, Boulet, Louis-Philippe, Cockcroft, Donald W., Davis, Beth E., Korn, Stephanie, Kornmann, Oliver, Leigh, Richard, Mayers, Irvin, Watz, Henrik, Grant, Sarah S., Jain, Monish, Cabanski, Maciej, Pertel, Peter E., Jones, Ieuan, Lecot, Jean R., Cao, Hui, O'Byrne, Paul M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996823/
https://www.ncbi.nlm.nih.gov/pubmed/36822634
http://dx.doi.org/10.1183/13993003.01193-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996823/
https://www.ncbi.nlm.nih.gov/pubmed/36822634
http://dx.doi.org/10.1183/13993003.01193-2022

Ejemplares similares